GSK plc Sponsored ADR (GSK)
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.
GSK Q2 Earnings Call Highlights
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and investment program intended to accelerate its late-stage pipeline and support growth beyond 2031.
GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)
GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as stock metrics like the forward P/E and dividend yield don't offer adequate support. While the company has maintained its long-term sales target, even that isn't encouraging enough from the stock price perspective as only limited price returns are foreseen.
GSK hits three-month high as vaccines help earnings top forecasts
GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. Revenue rose 5% to £8.41 billion, ahead of the £8.25 billion City consensus.
GSK (GSK) Beats Q2 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company's 2031 sales target.
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goal of keeping an aggressive bone cancer from worsening in a late-stage trial, just weeks after it succeeded in another advanced study.
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
Will GSK's Specialty Medicines Boost Q2 Revenue Growth?
GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK: Buy The Discount Before The Catalysts Close It
GSK (GSK) trades at a 42% discount to pharma peers, despite resilient earnings projections through the dolutegravir patent cliff. The HIV franchise's shift to long-acting injectables, protected by new IP, is driving 30–44% growth and mitigating generic risk. Nuvalent acquisition brings two near-term oncology launches, expected to improve margins and offset dolutegravir LOE impact.
